Keros Therapeutics (KROS) Competitors $14.44 -0.03 (-0.21%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$14.20 -0.24 (-1.70%) As of 07/11/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. TWST, RXRX, GMTX, AGIO, DNLI, BEAM, VCEL, KNSA, CGON, and BLTEShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), CG Oncology (CGON), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Twist Bioscience Recursion Pharmaceuticals Gemini Therapeutics Agios Pharmaceuticals Denali Therapeutics Beam Therapeutics Vericel Kiniksa Pharmaceuticals International CG Oncology Belite Bio Twist Bioscience (NASDAQ:TWST) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Which has more risk and volatility, TWST or KROS? Twist Bioscience has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Is TWST or KROS more profitable? Keros Therapeutics has a net margin of 1.96% compared to Twist Bioscience's net margin of -54.98%. Keros Therapeutics' return on equity of 0.75% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-54.98% -33.48% -25.34% Keros Therapeutics 1.96%0.75%0.69% Does the media refer more to TWST or KROS? In the previous week, Twist Bioscience had 6 more articles in the media than Keros Therapeutics. MarketBeat recorded 9 mentions for Twist Bioscience and 3 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.97 beat Twist Bioscience's score of 0.44 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, TWST or KROS? Keros Therapeutics has lower revenue, but higher earnings than Twist Bioscience. Keros Therapeutics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M7.28-$208.73M-$3.25-11.70Keros Therapeutics$3.55M165.23-$187.35M-$0.18-80.22 Do insiders and institutionals believe in TWST or KROS? 71.6% of Keros Therapeutics shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate TWST or KROS? Twist Bioscience presently has a consensus price target of $50.40, indicating a potential upside of 32.53%. Keros Therapeutics has a consensus price target of $30.56, indicating a potential upside of 111.60%. Given Keros Therapeutics' higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryKeros Therapeutics beats Twist Bioscience on 10 of the 16 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$587.71M$2.97B$5.62B$9.09BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-80.2220.7128.1320.27Price / Sales165.23288.27428.2698.57Price / CashN/A42.8637.4658.16Price / Book1.027.638.045.49Net Income-$187.35M-$55.05M$3.18B$250.45M7 Day Performance8.33%8.43%3.62%4.79%1 Month Performance5.87%5.42%4.06%7.68%1 Year Performance-69.56%2.03%30.01%16.43% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics1.9533 of 5 stars$14.44-0.2%$30.56+111.6%-68.6%$587.71M$3.55M-80.22100TWSTTwist Bioscience4.3757 of 5 stars$38.81-0.8%$50.40+29.9%-27.5%$2.32B$347.68M-11.93990Gap DownRXRXRecursion Pharmaceuticals2.0027 of 5 stars$5.73+2.4%$7.00+22.3%-31.3%$2.32B$58.84M-3.23400Analyst ForecastOptions VolumeGap DownGMTXGemini TherapeuticsN/A$52.97-0.8%N/A+26.6%$2.30BN/A-52.9730AGIOAgios Pharmaceuticals4.3881 of 5 stars$38.99-0.2%$58.60+50.3%-12.0%$2.25B$36.50M3.46390Insider TradeAnalyst RevisionDNLIDenali Therapeutics4.6418 of 5 stars$15.05+0.3%$33.71+124.1%-37.1%$2.19B$330.53M-5.63430News CoveragePositive NewsInsider TradeAnalyst RevisionBEAMBeam Therapeutics2.3037 of 5 stars$21.56+0.5%$48.75+126.1%-18.2%$2.17B$63.58M-4.67510News CoverageVCELVericel3.7197 of 5 stars$42.37+2.1%$61.14+44.3%-19.2%$2.13B$237.22M1,412.64300Positive NewsKNSAKiniksa Pharmaceuticals International3.5477 of 5 stars$28.88+0.3%$39.33+36.2%+30.0%$2.11B$481.17M-115.52220Analyst ForecastCGONCG Oncology2.4271 of 5 stars$27.29+0.9%$56.80+108.1%-22.5%$2.08B$662K-18.0861Analyst UpgradeBLTEBelite Bio2.3688 of 5 stars$62.39-2.8%$96.67+54.9%+29.2%$1.99BN/A-45.8810News CoverageAnalyst Revision Related Companies and Tools Related Companies Twist Bioscience Alternatives Recursion Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives Beam Therapeutics Alternatives Vericel Alternatives Kiniksa Pharmaceuticals International Alternatives CG Oncology Alternatives Belite Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
